PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBIT growth of 27.70% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
27.70%
Operating income growth of 27.70% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
-117.18%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-117.27%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-117.27%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.72%
Negative OCF growth while Biotechnology median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-138.72%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
64.97%
OCF/share CAGR of 64.97% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
64.97%
5Y OCF/share growth exceeding 1.5x Biotechnology median of 8.95%. Joel Greenblatt might see a strong moat or efficient cost structure driving outperformance.
27.61%
3Y OCF/share growth near Biotechnology median. Charlie Munger would find it typical for industry-level short-term expansions.
64.19%
Net income/share CAGR exceeding 1.5x Biotechnology median of 23.45% over a decade. Joel Greenblatt might see a standout compounder of earnings.
64.19%
5Y net income/share CAGR > 1.5x Biotechnology median of 35.12%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-5.53%
Negative 3Y CAGR while Biotechnology median is 43.32%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.11%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.50%
Negative BV/share change while Biotechnology median is -3.14%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.